No evidence that CD33 splicing SNP impacts the response to GO in younger adults with AML treated on UK MRC/NCRI trials

被引：39
作者：
Gale, Rosemary E. [1 ]
Popa, Teodora [1 ]
Wright, Melissa [2 ]
Khan, Naeem [3 ]
Freeman, Sylvie D. [3 ]
Burnett, Alan K. [4 ]
Russell, Nigel H. [5 ]
Hills, Robert K. [2 ]
Linch, David C. [1 ]
机构：
[1] UCL, Inst Canc, Dept Haematol, 72 Huntley St, London WC1E 6DD, England
[2] Cardiff Univ, Ctr Trials Res, Cardiff, S Glam, Wales
[3] Univ Birmingham, Dept Clin Immunol, Inst Immunol & Immunotherapy, Birmingham, W Midlands, England
[4] Cardiff Univ, Sch Med, Dept Haematol, Cardiff, S Glam, Wales
[5] Nottingham Univ Hosp NHS Trust, Dept Haematol, Nottingham, England
来源：
BLOOD | 2018年 / 131卷 / 04期
关键词：
ACUTE MYELOID-LEUKEMIA; GEMTUZUMAB OZOGAMICIN; INDUCTION CHEMOTHERAPY; ONCOLOGY-GROUP; EXPRESSION;
D O I：
10.1182/blood-2017-08-802157
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：468 / 471
页数：4
相关论文
共 9 条
[1]   Defining the dose of gemtuzumab ozogamicin in combination with induction chemotherapy in acute myeloid leukemia: a comparison of 3 mg/m2 with 6 mg/m2 in the NCRI AML17 Trial [J].
Burnett, Alan ;
Cavenagh, Jamie ;
Russell, Nigel ;
Hills, Robert ;
Kell, Jonathan ;
Jones, Gail ;
Nielsen, Ove Juul ;
Khwaja, Asim ;
Thomas, Ian ;
Clark, Richard .
HAEMATOLOGICA, 2016, 101 (06) :724-731
[2]   Identification of Patients With Acute Myeloblastic Leukemia Who Benefit From the Addition of Gemtuzumab Ozogamicin: Results of the MRC AML15 Trial [J].
Burnett, Alan K. ;
Hills, Robert K. ;
Milligan, Donald ;
Kjeldsen, Lars ;
Kell, Jonathan ;
Russell, Nigel H. ;
Yin, John A. L. ;
Hunter, Ann ;
Goldstone, Anthony H. ;
Wheatley, Keith .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04) :369-377
[3]   Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials [J].
Hills, Robert K. ;
Castaigne, Sylvie ;
Appelbaum, Frederick R. ;
Delaunay, Jacques ;
Petersdorf, Stephen ;
Othus, Megan ;
Estey, Elihu H. ;
Dombret, Herve ;
Chevret, Sylvie ;
Ifrah, Norbert ;
Cahn, Jean-Yves ;
Recher, Christian ;
Chilton, Lucy ;
Moorman, Anthony V. ;
Burnett, Alan K. .
LANCET ONCOLOGY, 2014, 15 (09) :986-996
[4]   Expression of CD33 is a predictive factor for effect of gemtuzumab ozogamicin at different doses in adult acute myeloid leukaemia [J].
Khan, N. ;
Hills, R. K. ;
Virgo, P. ;
Couzens, S. ;
Clark, N. ;
Gilkes, A. ;
Richardson, P. ;
Knapper, S. ;
Grimwade, D. ;
Russell, N. H. ;
Burnett, A. K. ;
Freeman, S. D. .
LEUKEMIA, 2017, 31 (05) :1059-1068
[5]   CD33 Splicing Polymorphism Determines Gemtuzumab Ozogamicin Response in De Novo Acute Myeloid Leukemia: Report From Randomized Phase III Children's Oncology Group Trial AAML0531 [J].
Lamba, Jatinder K. ;
Chauhan, Lata ;
Shin, Miyoung ;
Loken, Michael R. ;
Pollard, Jessica A. ;
Wang, Yi-Cheng ;
Ries, Rhonda E. ;
Aplenc, Richard ;
Hirsch, Betsy A. ;
Raimondi, Susana C. ;
Walter, Roland B. ;
Bernstein, Irwin D. ;
Gamis, Alan S. ;
Alonzo, Todd A. ;
Meshinchi, Soheil .
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (23) :2674-+
[6]  
Leith CP, 1999, BLOOD, V94, P1086
[7]   The level of blast CD33 expression positively impacts the effect of gemtuzumab ozogamicin in patients with acute myeloid leukemia [J].
Olombel, Guillaume ;
Guerin, Estelle ;
Guy, Julien ;
Perrot, Jean-Yves ;
Dumezy, Florent ;
de labarthe, Adrienne ;
Bastie, Jean-Noel ;
Legrand, Ollivier ;
Raffoux, Emmanuel ;
Plesa, Adriana ;
Wagner-Ballon, Orianne ;
Cornet, Edouard ;
Salaun, Veronique ;
Preudhomme, Claude ;
Thomas, Xavier ;
Pautas, Cecile ;
Chantepie, Sylvain ;
Turlure, Pascal ;
Castaigne, Sylvie ;
Dombret, Herve ;
Feuillard, Jean .
BLOOD, 2016, 127 (17) :2157-+
[8]   CD33 Expression and Its Association With Gemtuzumab Ozogamicin Response: Results From the Randomized Phase III Children's Oncology Group Trial AAML0531 [J].
Pollard, Jessica A. ;
Loken, Michael ;
Gerbing, Robert B. ;
Raimondi, Susana C. ;
Hirsch, Betsy A. ;
Aplenc, Richard ;
Bernstein, Irwin D. ;
Gamis, Alan S. ;
Alonzo, Todd A. ;
Meshinchi, Soheil .
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (07) :747-+
[9]   CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy [J].
Walter, Roland B. ;
Gooley, Ted A. ;
van der Velden, Vincent H. J. ;
Loken, Michael R. ;
van Dongen, Jacques J. M. ;
Flowers, David A. ;
Bernstein, Irwin D. ;
Appelbaum, Frederick R. .
BLOOD, 2007, 109 (10) :4168-4170
1